Literature DB >> 30659022

MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.

Qianyu Guo1,2, Vivian Z Li2, Jessica N Nichol2, Fan Huang1,2, William Yang1,2, Samuel E J Preston1,2, Zahra Talat2, Hanne Lefrère3, Henry Yu1,2, Guihua Zhang4, Mark Basik1,2, Christophe Gonçalves2, Yao Zhan1,2, Dany Plourde2, Jie Su2, Jose Torres1,2, Maud Marques2, Sara Al Habyan5, Krikor Bijian2, Frédéric Amant3, Michael Witcher1,2, Fariba Behbod6, Luke McCaffrey1,5, Moulay Alaoui-Jamali1,2, Nadia V Giannakopoulos7, Muriel Brackstone8, Lynne-Marie Postovit4,7, Sonia V Del Rincón9,2, Wilson H Miller9,2,10.   

Abstract

The mechanisms by which breast cancers progress from relatively indolent ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) are not well understood. However, this process is critical to the acquisition of metastatic potential. MAPK-interacting serine/threonine-protein kinase 1 (MNK1) signaling can promote cell invasion. NODAL, a morphogen essential for embryogenic patterning, is often reexpressed in breast cancer. Here we describe a MNK1/NODAL signaling axis that promotes DCIS progression to IDC. We generated MNK1 knockout (KO) or constitutively active MNK1 (caMNK1)-expressing human MCF-10A-derived DCIS cell lines, which were orthotopically injected into the mammary glands of mice. Loss of MNK1 repressed NODAL expression, inhibited DCIS to IDC conversion, and decreased tumor relapse and metastasis. Conversely, caMNK1 induced NODAL expression and promoted IDC. The MNK1/NODAL axis promoted cancer stem cell properties and invasion in vitro. The MNK1/2 inhibitor SEL201 blocked DCIS progression to invasive disease in vivo. In clinical samples, IDC and DCIS with microinvasion expressed higher levels of phospho-MNK1 and NODAL versus low-grade (invasion-free) DCIS. Cumulatively, our data support further development of MNK1 inhibitors as therapeutics for preventing invasive disease. SIGNIFICANCE: These findings provide new mechanistic insight into progression of ductal carcinoma and support clinical application of MNK1 inhibitors to delay progression of indolent ductal carcinoma in situ to invasive ductal carcinoma. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30659022      PMCID: PMC6513674          DOI: 10.1158/0008-5472.CAN-18-1602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  MNK1 kinase activity is required for abscission.

Authors:  Yoann Rannou; Patrick Salaun; Christelle Benaud; Jabbar Khan; Stéphanie Dutertre; Régis Giet; Claude Prigent
Journal:  J Cell Sci       Date:  2012-03-27       Impact factor: 5.285

2.  Mnk kinases in cytokine signaling and regulation of cytokine responses.

Authors:  Sonali Joshi; Leonidas C Platanias
Journal:  Biomol Concepts       Date:  2015-03

3.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.

Authors:  Takeshi Ueda; Masato Sasaki; Andrew J Elia; Iok In Christine Chio; Koichi Hamada; Rikiro Fukunaga; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness.

Authors:  Jolanta M Topczewska; Lynne-Marie Postovit; Naira V Margaryan; Anthony Sam; Angela R Hess; William W Wheaton; Brian J Nickoloff; Jacek Topczewski; Mary J C Hendrix
Journal:  Nat Med       Date:  2006-07-30       Impact factor: 53.440

5.  The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.

Authors:  James E Beggs; Shuye Tian; Greg G Jones; Jianling Xie; Valentina Iadevaia; Veronika Jenei; Gareth Thomas; Christopher G Proud
Journal:  Biochem J       Date:  2015-04-01       Impact factor: 3.857

6.  p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Authors:  C Lodillinsky; E Infante; A Guichard; R Chaligné; L Fuhrmann; J Cyrta; M Irondelle; E Lagoutte; S Vacher; H Bonsang-Kitzis; M Glukhova; F Reyal; I Bièche; A Vincent-Salomon; P Chavrier
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 7.  Reprogramming metastatic tumour cells with embryonic microenvironments.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jennifer Kasemeier-Kulesa; Paul M Kulesa; Lynne-Marie Postovit
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

8.  Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.

Authors:  Qinglin Li; Gabriel Eades; Yuan Yao; Yongshu Zhang; Qun Zhou
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

9.  Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.

Authors:  S Liu; J Zha; M Lei
Journal:  Clin Transl Oncol       Date:  2017-08-01       Impact factor: 3.405

10.  Embryonic protein nodal promotes breast cancer vascularization.

Authors:  Daniela F Quail; Logan A Walsh; Guihua Zhang; Scott D Findlay; Juan Moreno; Laura Fung; Amber Ablack; John D Lewis; Susan J Done; David A Hess; Lynne-Marie Postovit
Journal:  Cancer Res       Date:  2012-08-01       Impact factor: 12.701

View more
  14 in total

Review 1.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

2.  Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Sandeep Artham; Mir S Adil; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2019-06-14       Impact factor: 5.858

3.  Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.

Authors:  Samuel E J Preston; Audrey Emond; Filippa Pettersson; Daphné Dupéré-Richer; Madelyn Jean Abraham; Alberto Riva; Mena Kinal; Ryan N Rys; Nathalie A Johnson; Koren K Mann; Sonia V Del Rincón; Jonathan D Licht; Wilson H Miller
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

4.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 5.  Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer.

Authors:  Celia Pinto-Díez; Raquel Ferreras-Martín; Rebeca Carrión-Marchante; Víctor M González; María Elena Martín
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

6.  FAP-a and GOLPH3 Are Hallmarks of DCIS Progression to Invasive Breast Cancer.

Authors:  Li-Na Yu; Zhen Liu; Yan Tian; Pei-Pei Zhao; Xing Hua
Journal:  Front Oncol       Date:  2019-12-17       Impact factor: 6.244

Review 7.  Cancer Plasticity: The Role of mRNA Translation.

Authors:  Laura J Lee; David Papadopoli; Michael Jewer; Sonia Del Rincon; Ivan Topisirovic; Mitchell G Lawrence; Lynne-Marie Postovit
Journal:  Trends Cancer       Date:  2020-10-13

Review 8.  The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.

Authors:  Sathyen A Prabhu; Omar Moussa; Wilson H Miller; Sonia V Del Rincón
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

9.  Inhibitory effects of SEL201 in acute myeloid leukemia.

Authors:  Ewa M Kosciuczuk; Aroop K Kar; Gavin T Blyth; Mariafausta Fischietti; Sameem Abedin; Alain A Mina; Rebekah Siliezar; Tomasz Rzymski; Krzysztof Brzozka; Elizabeth A Eklund; Elspeth M Beauchamp; Frank Eckerdt; Diana Saleiro; Leonidas C Platanias
Journal:  Oncotarget       Date:  2019-12-24

10.  Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.

Authors:  Bart Kolendowski; Yudith Ramos Valdes; Hal Hirte; Hiroaki Itamochi; Wonjae Lee; Mark Carey; Trevor G Shepherd; Gabriel E DiMattia
Journal:  Cells       Date:  2020-11-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.